Saturday 17 October 2026
Export CYTK’s income statement to Excel — free account
Cytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024. In the quarter to June 2026, revenue fell 57.1%, EPS fell 33.9%, free cash flow fell 24.0% and total debt rose 57.7%, each against the same quarter a year earlier.
61.95
1.97
−3.08%
Follow CYTK
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
32.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
6 | 3 | 4 | 1 | 6 | 2 | 2 | 1 | 5 | 2 |
P/S ratio |
4.65 | 32.34 | 10.92 | 22.74 | 24.02 | 49.76 | 42.12 | 1,078.30 | 285.13 | 86.68 |
Altman Z-Score |
1.45 | (2.00) | (4.00) | (3.13) | (0.17) | 1.52 | (0.11) | (0.81) | (1.10) | (1.98) |
Altman Z″-Score (non-manufacturers) |
(3.05) | (3.72) | (8.40) | (7.36) | (1.52) | (2.12) | (2.75) | (8.55) | (4.60) | (7.91) |
P/FCF ratio |
13.98 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
6.36 | (17.96) | (27.90) | (32.06) | 25.71 | (78.33) | (40.57) | (109.67) | (80.33) | (53.50) |
Beneish M-Score |
4.43 | 333.25 | (1.89) | 48.31 | (3.17) | 6.19 | (4.38) | 93.98 | 2.34 | (0.44) |
P/B ratio |
5.25 | 3.94 | 13.26 | 0.00 | 11.83 | 14.37 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
5.25 | 3.94 | 13.26 | 0.00 | 11.83 | 14.37 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
3.47 | 15.34 | 5.96 | 19.34 | 18.19 | 45.30 | 40.30 | 1,078.65 | 262.46 | 89.80 |
EV/EBITDA |
18.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
9.98 | (2.01) | (1.85) | (5.72) | 113.52 | (22.39) | (12.73) | (19.60) | (12.25) | (15.50) |
EV/FCF |
10.42 | (1.96) | (1.84) | (5.56) | (481.39) | (16.67) | (12.26) | (19.54) | (12.13) | (14.78) |
Quick Ratio |
4.70 | 8.32 | 9.05 | 8.85 | 15.02 | 7.28 | 9.25 | 6.00 | 6.08 | 4.45 |
Current Ratio |
4.77 | 8.45 | 9.36 | 8.98 | 15.20 | 7.45 | 9.40 | 6.12 | 6.17 | 4.53 |
Net Debt/EBITDA |
(6.50) | 2.13 | 1.78 | 0.93 | 3.53 | 1.71 | 0.54 | (0.01) | 0.80 | (0.46) |
Debt/Assets |
17.56% | 10.78% | 20.08% | 46.33% | 25.99% | 18.76% | 60.17% | 74.90% | 46.88% | 81.23% |
Debt/Equity |
0.32 | 0.29 | 1.64 | (12.28) | 1.22 | 0.65 | (5.66) | (1.60) | (4.85) | (1.75) |
Asset Turnover |
0.75 | 0.06 | 0.12 | 0.11 | 0.14 | 0.10 | 0.10 | 0.01 | 0.02 | 0.06 |
Operating CF/Net income |
2.25 | 0.80 | 0.95 | 0.75 | (0.07) | 0.66 | 0.77 | 0.79 | 0.67 | 0.65 |
Capex/Depreciation |
(2.11) | (1.50) | (0.71) | (2.03) | (6.04) | (21.47) | (1.95) | (0.12) | (0.41) | (2.45) |
Interest Coverage |
6.93 | (6.67) | (4.12) | (3.61) | (2.43) | (6.35) | (6.34) | (8.60) | (6.20) | (5.89) |
| 20.19% | (125.16%) | (156.57%) | (1,622.88%) | (248.50%) | (120.54%) | (572.15%) | 212.96% | 226.00% | 197.47% | |
| 11.53% | (54.97%) | (42.01%) | (48.58%) | (30.91%) | (31.32%) | (41.91%) | (57.23%) | (52.97%) | (55.55%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
12.75% | (52.07%) | (56.33%) | (57.33%) | (27.89%) | (40.09%) | (49.17%) | (88.58%) | (59.30%) | (98.90%) |
Average Days of Receivables |
0.08 | 30.36 | 25.85 | 70.14 | 28.90 | 268.56 | 0.57 | 62.19 | 328.96 | 73.65 |
Research and Development Expense of Revenue |
56.29% | 675.46% | 282.96% | 320.55% | 173.66% | 227.09% | 254.59% | 4,384.10% | 1,837.22% | 472.55% |
Selling, General and Administrative Expense of Revenue |
26.15% | 272.80% | 99.30% | 147.42% | 94.61% | 137.45% | 188.16% | 2,305.60% | 1,165.50% | 322.89% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6.72% | 67.53% | 30.99% | 40.04% | 31.56% | 38.10% | 50.59% | 957.04% | 529.61% | 127.54% |
Graham Net Nets |
0.17 | 0.21 | 0.07 | (0.11) | 0.04 | (0.02) | (0.08) | (0.07) | (0.08) | (0.15) |
Graham Number |
4.49 | 0.00 | 0.00 | 3.01 | 0.00 | 0.00 | 10.72 | 22.15 | 11.96 | 28.41 |
Earnings Yield |
3.06% | (29.37%) | (30.85%) | (19.98%) | (9.67%) | (6.21%) | (9.58%) | (6.48%) | (11.18%) | (10.28%) |
Free Cash Flow Yield |
7.15% | (24.21%) | (29.68%) | (15.31%) | (0.16%) | (5.46%) | (7.80%) | (5.12%) | (7.59%) | (7.01%) |
Revenue per Share |
2.66 | 0.27 | 0.58 | 0.47 | 0.87 | 0.92 | 1.05 | 0.08 | 0.17 | 0.73 |
Operating CF per Share |
0.93 | (2.06) | (1.86) | (1.58) | 0.14 | (1.85) | (3.33) | (4.29) | (3.54) | (4.25) |
Capex per Share |
(0.04) | (0.06) | (0.02) | (0.05) | (0.17) | (0.64) | (0.13) | (0.01) | (0.03) | (0.21) |
Free Cash Flow per Share |
0.89 | (2.12) | (1.88) | (1.62) | (0.03) | (2.49) | (3.46) | (4.31) | (3.57) | (4.45) |
Cash per Share |
3.91 | 5.44 | 3.65 | 3.91 | 7.19 | 6.13 | 8.71 | 6.37 | 9.61 | 7.35 |
Shareholders Equity per Share |
2.36 | 2.22 | 0.48 | (0.19) | 1.76 | 3.17 | (1.20) | (4.00) | (1.21) | (5.49) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.36 | 2.22 | 0.48 | (0.19) | 1.76 | 3.17 | (1.20) | (4.00) | (1.21) | (5.49) |
Free Cash Flow |
35.42 | (104.64) | (102.09) | (93.53) | (2.11) | (191.39) | (310.85) | (415.75) | (399.80) | (534.82) |
Working Capital |
125.38 | 241.85 | 185.48 | 207.73 | 443.02 | 463.81 | 710.57 | 525.37 | 928.27 | 714.52 |
Capital Expenditures |
(1.56) | (2.88) | (0.87) | (2.62) | (11.05) | (48.87) | (11.33) | (1.42) | (3.91) | (24.81) |
Net Current Asset Value |
82.85 | 89.33 | 22.43 | (67.00) | 53.80 | (61.78) | (327.49) | (582.59) | (429.10) | (1,167.19) |
EV/EBIT |
19.74 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.22 | 0.03 | 0.10 | 0.20 | 0.69 | 0.12 | 0.19 | 0.21 | 0.28 |
Price to Operating Income |
26.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.20 | 0.54 | 0.39 | 0.29 | 0.14 | 0.03 | 0.07 | 0.17 | 0.14 | 0.13 |
Cash ROIC |
12.63% | (25.49%) | (38.22%) | (26.84%) | (0.29%) | (21.92%) | (24.19%) | (49.15%) | (25.02%) | (38.76%) |
Accounts Receivable Turnover |
5,911.50 | 23.54 | 18.85 | 7.27 | 11.65 | 2.50 | 3.64 | 10.53 | 2.06 | 5.12 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.02 | 0.57 | 1.67 | 3.70 | 4.79 | 28.12 | 25.98 | 0.72 | 8.97 | 17.21 |
Average Payables |
3.24 | 4.74 | 4.51 | 5.96 | 8.11 | 14.57 | 23.35 | 23.56 | 20.94 | 21.35 |
Average Assets |
142.69 | 232.48 | 252.99 | 250.50 | 411.81 | 687.56 | 928.05 | 919.55 | 1,112.99 | 1,413.11 |
Average Common Equity |
81.48 | 102.10 | 67.89 | 7.50 | 51.22 | 178.62 | 67.98 | (247.11) | (260.85) | (397.50) |
Columns are period end dates